Zalifrelimab
Modify Date: 2024-01-03 13:32:25
Zalifrelimab structure
|
Common Name | Zalifrelimab | ||
|---|---|---|---|---|
| CAS Number | 2148321-69-9 | Molecular Weight | N/A | |
| Density | N/A | Boiling Point | N/A | |
| Molecular Formula | N/A | Melting Point | N/A | |
| MSDS | N/A | Flash Point | N/A | |
Use of ZalifrelimabZalifrelimab (AGEN1884) is a fully human IgG1 monoclonal antibody targeting CTLA-4 (CTLA-4). Zalifrelimab antagonizes the inhibitory checkpoints of immune cell activation regulated by CTLA-4 signaling[1]. |
| Name | Zalifrelimab |
|---|
| Description | Zalifrelimab (AGEN1884) is a fully human IgG1 monoclonal antibody targeting CTLA-4 (CTLA-4). Zalifrelimab antagonizes the inhibitory checkpoints of immune cell activation regulated by CTLA-4 signaling[1]. |
|---|---|
| Related Catalog | |
| In Vitro | Zalifrelimab（AGEN1884；0.1、1、10 或 100 μg/mL）有效增强抗原特异性 T 细胞反应性，可与其他免疫调节抗体联合使用。Zalifrelimab 与 PD-1 阻断剂有效结合，可在外周引起 T 细胞增殖反应[2]。 |
| In Vivo | Zalifrelimab（AGEN1884；10 mg/kg；静脉注射；第 1 天和第 29 天）在非人灵长类动物中具有良好的耐受性，可增强疫苗介导的抗原特异性免疫[2]。 Animal Model: Cynomolgus macaques (Macaca fascicularis)[2] Dosage: 10 mg/kg Administration: i.v.; on days 1 and 29 Result: Enhanced antigen-specific immune responses in combination with reporter vaccines in vivo. |
| References |
| No Any Chemical & Physical Properties |